Abstract |
The administration of antibiotics decreases bacterial translocation, reduces the activity of nitric oxide synthase and improves the gas exchange of hepatopulmonary syndrome (HPS) in rats. We hypothesized that levofloxacin could reduce HPS-induced respiratory mechanical inhomogeneities and airway and pulmonary vascular remodeling. We assessed the respiratory mechanical properties and lung tissue structure in 24 rats assigned to the control, HPS (eHPS) and HPS+levofloxacin (eHPS+L) groups. The administration of levofloxacin reduced the HPS-induced chest wall but not the lung mechanical inhomogeneities. The eHPS airway proportion of elastic fibers increased 20% but was similar between the control and eHPS+L groups. The eHPS vascular collagen increased 25% in eHPS but was similar between the control and eHPS+L groups. Compared to the control group, the vascular proportion of elastic fibers of the eHPS and eHPS+L groups increased by 60% and 16%, respectively. The administration of levofloxacin decreased the HPS-induced chest wall mechanical inhomogeneities and airway and vascular remodeling.
|
Authors | Eduardo Gaio, Veronica Amado, Leonardo Rangel, Wilson Huang, Rodrigo Storck, César Augusto Melo-Silva |
Journal | Respiratory physiology & neurobiology
(Respir Physiol Neurobiol)
Vol. 189
Issue 3
Pg. 565-70
(Dec 01 2013)
ISSN: 1878-1519 [Electronic] Netherlands |
PMID | 23994178
(Publication Type: Journal Article)
|
Copyright | Copyright © 2013 Elsevier B.V. All rights reserved. |
Chemical References |
- Membrane Proteins
- Topoisomerase II Inhibitors
- ligatin
- Levofloxacin
|
Topics |
- Airway Remodeling
(drug effects, physiology)
- Animals
- Cholestasis
(complications)
- Disease Models, Animal
- Hepatopulmonary Syndrome
(complications, etiology, physiopathology)
- Levofloxacin
(therapeutic use)
- Lung
(drug effects, pathology)
- Male
- Membrane Proteins
(adverse effects)
- Pulmonary Artery
(drug effects)
- Rats
- Rats, Wistar
- Respiratory Muscles
(drug effects)
- Statistics, Nonparametric
- Thoracic Wall
(drug effects)
- Topoisomerase II Inhibitors
(therapeutic use)
|